49 related articles for article (PubMed ID: 15675305)
1. [The filter region of the myocardial Na channel, together with ion selectivity, controls pharmacodynamics of anti-arrhythmia agents--an analysis using the channel altered by idiopathic ventricular fibrillation].
Sasaki K
Hokkaido Igaku Zasshi; 2004 Nov; 79(6):747-54. PubMed ID: 15675305
[No Abstract] [Full Text] [Related]
2. Unexpected mexiletine responses of a mutant cardiac Na+ channel implicate the selectivity filter as a structural determinant of antiarrhythmic drug access.
Sasaki K; Makita N; Sunami A; Sakurada H; Shirai N; Yokoi H; Kimura A; Tohse N; Hiraoka M; Kitabatake A
Mol Pharmacol; 2004 Aug; 66(2):330-6. PubMed ID: 15266024
[TBL] [Abstract][Full Text] [Related]
3. A common SCN5A variant alters the responsiveness of human sodium channels to class I antiarrhythmic agents.
Shuraih M; Ai T; Vatta M; Sohma Y; Merkle EM; Taylor E; Li Z; Xi Y; Razavi M; Towbin JA; Cheng J
J Cardiovasc Electrophysiol; 2007 Apr; 18(4):434-40. PubMed ID: 17331104
[TBL] [Abstract][Full Text] [Related]
4. Mutation-specific effects of lidocaine in Brugada syndrome.
Clancy CE; Wehrens XH
Int J Cardiol; 2007 Oct; 121(3):249-52. PubMed ID: 17761312
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacokinetics and pharmacodynamics of class I antiarrhythmic agents after a single oral administration].
Yokota M; Toyama J; Ukai M; Miyahara T; Koide M; Kato R; Yasui S; Sotobata I
Jpn Circ J; 1992; 56 Suppl 5():1480-4. PubMed ID: 1291746
[No Abstract] [Full Text] [Related]
6. Selective block of late currents in the DeltaKPQ Na(+) channel mutant by pilsicainide and lidocaine with distinct mechanisms.
Ono K; Kaku T; Makita N; Kitabatake A; Arita M
Mol Pharmacol; 2000 Feb; 57(2):392-400. PubMed ID: 10648650
[TBL] [Abstract][Full Text] [Related]
7. Setting up for the block: the mechanism underlying lidocaine's use-dependent inhibition of sodium channels.
Cummins TR
J Physiol; 2007 Jul; 582(Pt 1):11. PubMed ID: 17525109
[No Abstract] [Full Text] [Related]
8. A paradoxical effect of lidocaine for the N406S mutation of SCN5A associated with Brugada syndrome.
Itoh H; Tsuji K; Sakaguchi T; Nagaoka I; Oka Y; Nakazawa Y; Yao T; Jo H; Ashihara T; Ito M; Horie M; Imoto K
Int J Cardiol; 2007 Oct; 121(3):239-48. PubMed ID: 17445919
[TBL] [Abstract][Full Text] [Related]
9. Mexiletine and tocainide: orally active congeners of lidocaine.
Wulf BG
Clin Pharm; 1983; 2(4):340-6. PubMed ID: 6411416
[No Abstract] [Full Text] [Related]
10. Differential contribution of sodium channel subtypes to action potential generation in unmyelinated human C-type nerve fibers.
Lang PM; Hilmer VB; Grafe P
Anesthesiology; 2007 Sep; 107(3):495-501. PubMed ID: 17721253
[TBL] [Abstract][Full Text] [Related]
11. Class IB antiarrhythmic drugs: tocainide, mexiletine, and moricizine.
Snyder DW
J La State Med Soc; 1989 May; 141(5):21-5. PubMed ID: 2499645
[TBL] [Abstract][Full Text] [Related]
12. [Brugada syndrome occurring in an identical twin: a case report].
Sakabe M; Fujiki A; Tsuneda T; Nishida K; Sugao M; Mizumaki K; Inoue H
J Cardiol; 2002 Sep; 40(3):111-5. PubMed ID: 12325460
[TBL] [Abstract][Full Text] [Related]
13. Class Ic antiarrhythmics block human skeletal muscle Na channel during myotonia-like stimulation.
Aoike F; Takahashi MP; Sakoda S
Eur J Pharmacol; 2006 Feb; 532(1-2):24-31. PubMed ID: 16473348
[TBL] [Abstract][Full Text] [Related]
14. Class I and IV antiarrhythmic drugs and cytosolic calcium regulate mRNA encoding the sodium channel alpha subunit in rat cardiac muscle.
Duff HJ; Offord J; West J; Catterall WA
Mol Pharmacol; 1992 Oct; 42(4):570-4. PubMed ID: 1331749
[TBL] [Abstract][Full Text] [Related]
15. Lidocaine does not affect myocardial electrical heterogeneity: implications for low proarrhythmic actions.
Sims JJ; Winecoff AP; Ujhelyi MR
Pharmacotherapy; 1997; 17(6):1267-73. PubMed ID: 9399610
[TBL] [Abstract][Full Text] [Related]
16. [Ion channels and arrhythmias].
Borchard U; Hafner D
Z Kardiol; 2000; 89 Suppl 3():6-12. PubMed ID: 10810780
[TBL] [Abstract][Full Text] [Related]
17. Mexiletine-responsive erythromelalgia due to a new Na(v)1.7 mutation showing use-dependent current fall-off.
Choi JS; Zhang L; Dib-Hajj SD; Han C; Tyrrell L; Lin Z; Wang X; Yang Y; Waxman SG
Exp Neurol; 2009 Apr; 216(2):383-9. PubMed ID: 19162012
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of intravenous agents for ventricular arrhythmias.
Nolan PE
Pharmacotherapy; 1997; 17(2 Pt 2):65S-75S; discussion 89S-91S. PubMed ID: 9085342
[TBL] [Abstract][Full Text] [Related]
19. The role of late I and antiarrhythmic drugs in EAD formation and termination in Purkinje fibers.
Fedida D; Orth PM; Hesketh JC; Ezrin AM
J Cardiovasc Electrophysiol; 2006 May; 17 Suppl 1():S71-S78. PubMed ID: 16686685
[TBL] [Abstract][Full Text] [Related]
20. Mexiletine and tocainide: a profile of two lidocaine analogs.
Woosley RL
Ration Drug Ther; 1987 Mar; 21(3):1-7. PubMed ID: 3116601
[No Abstract] [Full Text] [Related]
[Next] [New Search]
